Neurodegenerative diseases affect cells in the nervous system called neurons. Twenty million people worldwide are diagnosed with a neurodegenerative disease each year, and at present they are all progressive and incurable.
The Chandran group links clinical activity with laboratory research into two such conditions: multiple sclerosis and motor neurone disease. Measuring disease course and treatment outcomes through disease bio-registers builds an increasingly accurate clinical picture.
In parallel, studies in the lab —including using human stem cells—focus on understanding what is going wrong in the neurons and supporting cells called glia. Bringing these two strands together, the group aims to develop novel regenerative therapies and bring them to early-phase clinical trials.